mFOLFOX
Phase 2Small molecule
Arcus BiosciencesmFOLFOX is one of 134 small molecule programs targeting Rectal Adenocarcinoma. It is currently in Phase 2.
6
Indications
12
Total Trials
5
Active Trials
133
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Fluoropyrimidine
RochePhase 3
SHR-1210
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
mFOLFOX
Arcus BiosciencesPhase 2
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Glutamine
SanofiPreclinical
Induction Phase1
GenmabPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Biliary Tract Cancer2 trials
Gastric Cancer2 trials
Gastrointestinal1 trial
Rectal Adenocarcinoma1 trial
5 more indications
Locally Advanced Unresectable or Metastatic Solid Tumors1 trial
Patients With Locally Advanced Rectal Cancer1 trial
Locally-advanced Rectal Cancer1 trial
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Active, not recruiting·—·Phase 2·NCT04543695·255 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mFOLFOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company